Manara - Qatar Research Repository
Browse

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report

Download (1003.37 kB)
journal contribution
submitted on 2025-05-27, 11:14 and posted on 2025-05-27, 11:16 authored by Meshaal Alanzi, Mohammad Abu-Tineh, Lajos Szabados, MZ Sharaf Eldean, Sali Alatasi, Ruba Y Taha, Sarah A Elkourashy

Abstract

Although Burkitt lymphoma is considered a curable disease due to the progress made in choosing the most effective first-line therapy, relapsed or refractory Burkitt lymphoma (BL) has a very poor outcome. There is a lack of data supporting the treatment regimens. We report a 48-year-old male with stage II Burkitt’s lymphoma with no response to the first line of high-intensity chemotherapy. However, treatment with polatuzumab vedotin led to complete clinical remission for more than one year.

Other Information

Published in: OncoTargets and Therapy
License: https://creativecommons.org/licenses/by/4.0/
See article on publisher's website: https://dx.doi.org/10.2147/ott.s394193

Funding

Open Access funding provided by the Qatar National Library.

History

Language

  • English

Publisher

Dove Medical Press

Publication Year

  • 2023

License statement

This Item is licensed under the Creative Commons Attribution 4.0 International License.

Institution affiliated with

  • Hamad Medical Corporation
  • National Center for Cancer Care and Research - HMC
  • Weill Cornell Medicine - Qatar

Usage metrics

    Hamad Medical Corporation

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC